ORKA · Oruka Therapeutics, Inc.

The thesis

Oruka Therapeutics' psoriasis antibody ORKA-001 has passed its placebo-controlled test, and the December 2026 52-week EVERLAST-A results now decide whether that clearance lasts without further dosing. On this evidence the shares are modestly more likely to beat the S&P 500 than lag it over the next three months. The view is wrong if the shares close below $82 or if complete clearance at 52 weeks falls below the 63.5% Week 16 rate.

The clinical facts have not changed since the 26 October 2026 release: 61% of participants on 600 mg reached complete skin clearance at Week 16 in the 187-participant EVERLAST-B Phase 2b trial, against 0% on placebo. What has moved is the price. The adjusted daily close was $96.02 on 5 November 2026, up from $90.33 on 26 October 2026 and 15.1% below the 52-week high close of $113.08.

The narrative is maturing: the main readout is known, and Guggenheim, Wedbush and H.C. Wainwright all kept their targets unchanged on 27 October 2026 (Benzinga). Third-quarter results, listed by GuruFocus for 12 November 2026, are the next filed update on cash and share sales.

Bullish and bearish views on Oruka Therapeutics, Inc.

The bull case on Oruka Therapeutics, Inc. (ORKA), in brief: Primary endpoint met against placebo. The bear case: The case rests on 46 participants.

Bull case

• Primary endpoint met against placebo. Oruka's 26 October 2026 release reported PASI 100 (complete clearance on the Psoriasis Area and Severity Index) of 61% at 600 mg, 44% at 300 mg and 43% at 37.5 mg, against 0% on placebo. PASI 90 was 86% at the high dose.
• Larger trial matches the earlier one. EVERLAST-A reported PASI 100 of 63.5% (40 of 63) at Week 16 on 27 April 2026. The 61% high-dose result in EVERLAST-B, a randomized trial with a placebo arm, is close to that figure.
• Clearance deepened after dosing ended. Oruka reported on 23 September 2026 that EVERLAST-A PASI 100 reached 71.4% (45 of 63) at Week 28, with no dosing after Week 4. The 52-week results extend the same test.
• High-dose safety looks clean. Oruka reported on 26 October 2026 that 39% of high-dose participants had a treatment-emergent adverse event, against 43% on placebo. Across the 140 ORKA-001 participants, 3 serious events (2%) occurred, none in the high-dose arm and none judged treatment-related.
• Analyst targets sit above the shares. MarketBeat put the consensus target at $133.00 on 2 November 2026, from 10 Buy ratings and 1 Sell, with recent targets from $120 to $200. Benzinga headlines dated 27 October 2026 show Guggenheim at $200, Wedbush at $165 and H.C. Wainwright at $120; BTIG reiterated $151 on 19 October 2026.
• Cash covers the guided path. Oruka's 10 August 2026 second-quarter update reported $1.1 billion in cash, cash equivalents and marketable securities at 30 June, and said this funds the company through a biologics license application for ORKA-001.

Bear case

• The case rests on 46 participants. The 300 mg and 37.5 mg arms reached 44% and 43% complete clearance, so the 61% figure comes from the high-dose arm alone. That group is too small to fix a Phase 3 clearance rate.
• Mid-dose safety is uneven. Oruka reported adverse events in 60% of mid-dose participants on 26 October 2026, against 43% on placebo and 39% at the high dose. The company described rates as comparable across groups.
• Insiders sold steadily this autumn. MarketBeat counted 154,950 insider shares sold for $14,102,680 over the 90 days to 2 November 2026.
• Share supply can grow into strength. A $500 million at-the-market program with TD Cowen, which lets the company sell shares into the market over time, has been open since the 27 August 2026 prospectus supplement. Sales appear only in later filings, and the third-quarter report is the first to cover this period.
• Momentum looks stretched before the next events. The 14-day Relative Strength Index, a 0-to-100 momentum gauge, read 80.3 on 5 November 2026, up from 63.2 on 26 October 2026. MarketBeat put market value at $6.41 billion on 2 November 2026 for a company with no product sales.
• The last good readout faded. The adjusted close was $78.19 on 13 October 2026, less than three weeks after the positive Week 28 release of 23 September 2026.

Price setup

The adjusted daily close moved from $78.19 on 13 October 2026 to $90.33 on 26 October 2026, the day of the EVERLAST-B release, and to $96.02 on 5 November 2026. Over three months the shares are still down 8.7%, so the recent rise is a recovery within a lower range than the summer's. The 52-week high close is $113.08; MarketBeat's one-year intraday range is $25.23 to $115.51.

MarketBeat listed the 50-day moving average at $88.47 and the 200-day at $68.90 on 2 November 2026, and the shares trade above both. The $82 invalidation level carries over from the previous note. It sits between the $78.19 close before the readout and the $90.33 close on the readout day, so a close below it would give back most of that move.

Crowding evidence is mixed. The Relative Strength Index of 80.3, insider sales and the open at-the-market program point to selling pressure into strength. A Stocktwits report on 26 October 2026 described the day as the shares' best in over four months, which shows attention around the readout. MarketBeat reported institutions at 56.44% of shares and insiders at 23.49% on 2 November 2026.

Catalysts, next 30 days

• 10 November to 18 November 2026: Investor conferences, per BiopharmaWatch's listing of the company's 3 November 2026 announcement: Guggenheim on 10 November 2026, Stifel on 11 November 2026, UBS on 17 November 2026 and Jefferies on 18 November 2026. Any change to Phase 3 or EVERLAST-A timing would be new.
• ~12 November 2026, est.: Third-quarter 2026 results, on the date listed by GuruFocus; the company had not confirmed it in sources checked on 6 November 2026. The report shows cash at 30 September and any at-the-market sales.
• December 2026, company guidance: 52-week EVERLAST-A results for all participants. This is the main durability test and may fall just outside the 30-day window.
• 1Q 2027, company guidance: ORKA-002 Phase 2 Week 16 results in psoriasis.
• First half of 2027, company guidance: Planned ORKA-001 Phase 3 start at 600 mg, pending regulator discussions.

What would change the view

The case breaks if 52-week EVERLAST-A results show PASI 100 below the 63.5% Week 16 rate, because long-interval dosing is what separates ORKA-001 in this thesis. It also breaks if Oruka moves the Phase 3 start past the first half of 2027 or regulators require more dose-ranging work, since the company's cash guidance runs through a biologics license application.

A new safety signal would weaken the case: higher adverse-event or discontinuation rates in the high-dose arm in later EVERLAST-B or Phase 3 results. Large at-the-market sales disclosed in the third-quarter report would add supply without breaking the clinical case.

On price, a daily close below $82 ends the thesis. That level would erase most of the 26 October 2026 readout gain.

What it trades with

MarketBeat listed a beta of -0.34 on 2 November 2026, so the shares have not tracked the broad market closely. The dated moves above follow Oruka's own trial releases, and the next ones depend on the same program. ORKA-002 adds a second psoriasis readout in 1Q 2027, in the same disease, so it adds little separation from the ORKA-001 outcome.